What is Kiora Pharmaceuticals Inc?
, a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 3.19M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.